NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
TherapeuticsMD, Inc. TXMD
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.0M
▲ 71.6% vs FY2024
EPS · FY25
$-0.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-2.1%
Net margin · FY25
-18.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 19 cents on every revenue dollar this year.
Per share
USD -0.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-2.1%
Return on equity, FY2025
ROE
Operating margin-145.3%
Net margin-18.8%
Return on assets-1.5%
Each USD of equity lost 2 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−45.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−64.9%
−45.8%
−17.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+68.5%
Change, 10 years+440.2%
The share count grew 68% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 37.7M
total assets, end of FY2025
Total assetsUSD 37.7M
EquityUSD 26.9M
CashUSD 7.5M
Current ratio3.02×
Equity funds 71% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
0.0
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
EBITDA $B
·
·
−0.0
0.0
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
Income tax $B
·
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.05
−0.19
−0.99
11.96
−21.66
−0.67
−0.72
−0.59
−0.37
−0.46
−0.49
−0.36
−0.22
−0.38
−0.21
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−2.1
−7.7
−31.9
·
·
·
−330.1
−116.6
−59.8
−94.3
−152.7
−105.2
−106.7
·
·
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.30
0.27
0.24
0.22
0.20
0.18
0.16
0.14
0.10
0.08
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed